Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Proposed Sale · 144

HARMONY BIOSCIENCES HLDGS INC

HRMYNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Sep 17, 2026Accepted Sep 17, 2026, 4:34 PM EDTFiling CIK 2009762Accession 0001950047-26-009641
Share

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer
HARMONY BIOSCIENCES HLDGS INC
Issuer CIK
0001802665
SEC file number
001-39450
Phone
(484)-539-9800
Person for whose account securities are to be sold
KUMAR BUDUR
Relationships to issuer
Officer
Street
630 W Germantown Pike, Suite 215
City
Plymouth Meeting
State / country code
PA
Postal code
19462

Securities proposed for sale

Securities proposed for sale · 1 reported row
SecurityProposed unitsAggregate market valueUnits outstandingApproximate sale dateExchangeBroker / market maker
Common80033,768.0058,236,00009/17/2026NASDAQMorgan Stanley Smith Barney LLC Executive Financial Services

Broker / market maker — proposed row 1, entry 1

Name
Morgan Stanley Smith Barney LLC Executive Financial Services
Street
1 New York Plaza
Street (continued)
8th Floor
City
New York
State / country code
NY
Postal code
10004

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
SecurityAcquiredNature of acquisitionAcquired fromAmount acquiredGift transactionPayment dateNature of payment
Common09/17/2026Exercise of Stock OptionsIssuer800N09/17/2026Cash

Sales reported in the preceding three months

Sales reported in the preceding three months · 4 reported rows
SellerSecuritySale dateAmount soldGross proceeds
10b5-1 Sales for KUMAR BUDURCommon09/16/20261,80077,426.28
10b5-1 Sales for KUMAR BUDURCommon09/08/20265,500232,908.65
10b5-1 Sales for KUMAR BUDURCommon09/08/202622,954989,349.63
10b5-1 Sales for KUMAR BUDURCommon09/04/20265,500230,911.45

Seller — prior-sale row 1, entry 1

Name
10b5-1 Sales for KUMAR BUDUR
Street
630 W Germantown Pike, Suite 215
City
Plymouth Meeting
State / country code
PA
Postal code
19462

Seller — prior-sale row 2, entry 1

Name
10b5-1 Sales for KUMAR BUDUR
Street
630 W Germantown Pike, Suite 215
City
Plymouth Meeting
State / country code
PA
Postal code
19462

Seller — prior-sale row 3, entry 1

Name
10b5-1 Sales for KUMAR BUDUR
Street
630 W Germantown Pike, Suite 215
City
Plymouth Meeting
State / country code
PA
Postal code
19462

Seller — prior-sale row 4, entry 1

Name
10b5-1 Sales for KUMAR BUDUR
Street
630 W Germantown Pike, Suite 215
City
Plymouth Meeting
State / country code
PA
Postal code
19462

Prior-sale reporting

Nothing to report for the preceding three months
N

Notice signature

Notice date
09/17/2026
Signed
/s/ Kumar Budur
Plan adoption dates
06/05/2026

Company context

Harmony Biosciences is developing and commercializing innovative medicines for both rare and broad CNS disorders, and we are becoming an enduring leader in neuroscience. Our first medicine, WAKIX® (pitolisant), is the first and only FDA-approved non-scheduled treatment for excessive daytime sleepiness or cataplexy in patients 6 years of age and older with narcolepsy. Its launch ranks among the most successful in the history of orphan drugs. Building on our success and profitability, we are continuing to advance our novel clinical-stage pipeline, led by BP-205, an investigational orexin-2 receptor agonist with best-in-class potential across a broad range of CNS disorders. With a strong balance sheet, we have the capacity and conviction to pursue strategic business development opportunities. Harmony is guided by an unwavering commitment to patients and driven to create long-term value for shareholders. For more information, visit: www.harmonybiosciences.com.

Current securities

Recent company filings

  1. SCHEDULE 13G - filed by AMERICAN CENTURY INVESTMENT MANAGEMENT INC regarding Harmony Biosciences Holdings, Inc.Nov 16, 2026
  2. 10-Q filingNov 4, 2026
  3. Results of Operations and Financial Condition · Regulation FD DisclosureNov 4, 2026
  4. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 30, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 13, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.